Skip to main content
Erschienen in: Tumor Biology 5/2014

01.05.2014 | Research Article

Investigation of intercellular adhesion molecules (ICAMs) gene expressions in patients with Barrett's esophagus

verfasst von: Belgin Alasehirli, Elif Oğuz, Ebru Oksuzler, Irfan Koruk, Serdar Oztuzcu, Esma Ozkara, Metin Karakok, Ayse Binnur Erbagcı, Abdullah Tuncay Demiryurek

Erschienen in: Tumor Biology | Ausgabe 5/2014

Einloggen, um Zugang zu erhalten

Abstract

The adhesion molecules play a major role in inflammation as well as in neoplastic diseases. The aim of this study is to evaluate the expressions of the adhesion molecules, intercellular adhesion molecule 1 (ICAM-1), ICAM-2, and ICAM-3, in Barrett’s esophagus, recognized as a premalign lesion for esophageal cancer and related to inflammation. Eighteen patients with Barrett’s esophagus according to endoscopy and 25 volunteers without Barrett’s esophagus disease were included in the study. Tissue samples were supplied by biopsy and used for both gene expression and immunohistochemical analysis. The significance of the differences between the two groups was assessed by Student’s t test. The ICAM-1 expression level was fivefold higher in the patient group compared with that of the control. There was an increase in the serum level of ICAM-1 in patients compared to that of the controls, but this increase was not significant. ICAM-2 levels were also increased in the patient group, but it was not significant. There was no difference between controls and patients in ICAM-3 levels. Significantly higher levels of ICAM-1 gene expression make us think that ICAM-1 may play an important role in Barrett’s esophagus. We think that more studies, with larger patient groups and preferably detailed histopathological and clinical evaluations, are needed to explain the severity of ICAM-1, ICAM-2, and ICAM-3 molecules in Barrett’s esophagus.
Literatur
1.
Zurück zum Zitat Abdel-Latif MM, Duggan S, Reynolds JV, Kelleher D. Inflammation and esophageal carcinogenesis. Curr Opin Pharmacol. 2009;9(4):396–404.CrossRefPubMed Abdel-Latif MM, Duggan S, Reynolds JV, Kelleher D. Inflammation and esophageal carcinogenesis. Curr Opin Pharmacol. 2009;9(4):396–404.CrossRefPubMed
2.
Zurück zum Zitat Solaymani-Dodaran M, Logan RF, West J, Card T, Coupland C. Risk of oesophageal cancer in Barrett’s oesophagus and gastro-oesophageal reflux. Gut. 2004;53(8):1070–4.CrossRefPubMedPubMedCentral Solaymani-Dodaran M, Logan RF, West J, Card T, Coupland C. Risk of oesophageal cancer in Barrett’s oesophagus and gastro-oesophageal reflux. Gut. 2004;53(8):1070–4.CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat Hage M, Siersema PD, Van Dekken H, Steyerberg EW, Dees J, Kuipers EJ. Oesophageal cancer incidence and mortality in patients with long-segment Barrett’s oesophagus after a mean follow-up of 12.7 years. Scand J Gastroenterol. 2004;39(12):1175–9.CrossRefPubMed Hage M, Siersema PD, Van Dekken H, Steyerberg EW, Dees J, Kuipers EJ. Oesophageal cancer incidence and mortality in patients with long-segment Barrett’s oesophagus after a mean follow-up of 12.7 years. Scand J Gastroenterol. 2004;39(12):1175–9.CrossRefPubMed
4.
Zurück zum Zitat Poehlmann A, Kuester D, Malfertheiner P, Guenther T, Roessner A. Inflammation and Barrett’s carcinogenesis. Pathol Res Pract. 2012;208(5):269–80.CrossRefPubMed Poehlmann A, Kuester D, Malfertheiner P, Guenther T, Roessner A. Inflammation and Barrett’s carcinogenesis. Pathol Res Pract. 2012;208(5):269–80.CrossRefPubMed
5.
Zurück zum Zitat Fitzgerald RC, Abdalla S, Onwuegbusi BA, Sirieix P, Saeed IT, Burnham WR, et al. Inflammatory gradient in Barrett’s oesophagus: implications for disease complications. Gut. 2002;51(3):316–22.CrossRefPubMedPubMedCentral Fitzgerald RC, Abdalla S, Onwuegbusi BA, Sirieix P, Saeed IT, Burnham WR, et al. Inflammatory gradient in Barrett’s oesophagus: implications for disease complications. Gut. 2002;51(3):316–22.CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Moons LM, Kusters JG, van Delft JH, Kuipers EJ, Gottschalk R, Geldof H, et al. A pro-inflammatory genotype predisposes to Barrett’s esophagus. Carcinogenesis. 2008;29(5):926–31.CrossRefPubMed Moons LM, Kusters JG, van Delft JH, Kuipers EJ, Gottschalk R, Geldof H, et al. A pro-inflammatory genotype predisposes to Barrett’s esophagus. Carcinogenesis. 2008;29(5):926–31.CrossRefPubMed
7.
Zurück zum Zitat Nair KS, Naidoo R, Chetty R. Expression of cell adhesion molecules in oesophageal carcinoma and its prognostic value. J Clin Pathol. 2005;58(4):343–51.CrossRefPubMedPubMedCentral Nair KS, Naidoo R, Chetty R. Expression of cell adhesion molecules in oesophageal carcinoma and its prognostic value. J Clin Pathol. 2005;58(4):343–51.CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Juliano RL. Signal transduction by cell adhesion receptors and the cytoskeleton: functions of integrins, cadherins, selectins and immunoglobulin superfamily member. Annu Rev Pharmacol Toxicol. 2002;42:283–323.CrossRefPubMed Juliano RL. Signal transduction by cell adhesion receptors and the cytoskeleton: functions of integrins, cadherins, selectins and immunoglobulin superfamily member. Annu Rev Pharmacol Toxicol. 2002;42:283–323.CrossRefPubMed
9.
Zurück zum Zitat Hua S. Targeting sites of inflammation: intercellular adhesion molecule-1 as a target for novel inflammatory therapies. Front Pharmacol. 2013;4:127.PubMedPubMedCentral Hua S. Targeting sites of inflammation: intercellular adhesion molecule-1 as a target for novel inflammatory therapies. Front Pharmacol. 2013;4:127.PubMedPubMedCentral
10.
Zurück zum Zitat Hale JS, Li M, Lathia JD. The malignant social network: cell-cell adhesion and communication in cancer stem cells. Cell Adhes Migr. 2012;6(4):346–55.CrossRef Hale JS, Li M, Lathia JD. The malignant social network: cell-cell adhesion and communication in cancer stem cells. Cell Adhes Migr. 2012;6(4):346–55.CrossRef
11.
Zurück zum Zitat Van Assche G, Rutgeerts P. Physiological basis for novel drug therapies used to treat the inflammatory bowel diseases I. Immunology and therapeutic potential of antiadhesion molecule therapy in inflammatory bowel disease. Am J Physiol Gastrointest Liver Physiol. 2005;288:G169–74.CrossRefPubMed Van Assche G, Rutgeerts P. Physiological basis for novel drug therapies used to treat the inflammatory bowel diseases I. Immunology and therapeutic potential of antiadhesion molecule therapy in inflammatory bowel disease. Am J Physiol Gastrointest Liver Physiol. 2005;288:G169–74.CrossRefPubMed
12.
Zurück zum Zitat Bloemen PG, van den Tweel MC, Henricks PA, Engels F, Wagenaar SS, Rutten AA, et al. Expression and modulation of adhesion molecules on human bronchial epithelial cells. Am J Respir Cell Mol Biol. 1993;9(6):586–93.CrossRefPubMed Bloemen PG, van den Tweel MC, Henricks PA, Engels F, Wagenaar SS, Rutten AA, et al. Expression and modulation of adhesion molecules on human bronchial epithelial cells. Am J Respir Cell Mol Biol. 1993;9(6):586–93.CrossRefPubMed
13.
Zurück zum Zitat Lee IT, Yang CM. Inflammatory signalings involved in airway and pulmonary diseases. Mediators Inflamm. 2013;2013:791231.PubMedPubMedCentral Lee IT, Yang CM. Inflammatory signalings involved in airway and pulmonary diseases. Mediators Inflamm. 2013;2013:791231.PubMedPubMedCentral
14.
Zurück zum Zitat Sugitharini V, Prema A, Berla Thangam E. Inflammatory mediators of systemic inflammation in neonatal sepsis. Inflamm Res. 2013;62(12):1025–34.CrossRefPubMed Sugitharini V, Prema A, Berla Thangam E. Inflammatory mediators of systemic inflammation in neonatal sepsis. Inflamm Res. 2013;62(12):1025–34.CrossRefPubMed
15.
Zurück zum Zitat Grünberg K, Sterk PJ. Rhinovirus infections: induction and modulation of airways inflammation in asthma. Clin Exp Allergy. 1999;29 Suppl 2:65–73.PubMed Grünberg K, Sterk PJ. Rhinovirus infections: induction and modulation of airways inflammation in asthma. Clin Exp Allergy. 1999;29 Suppl 2:65–73.PubMed
16.
Zurück zum Zitat Kjaergaard AG, Dige A, Krog J, Tønnesen E, Wogensen L. Soluble adhesion molecules correlate with surface expression in an in vitro model of endothelial activation. Basic Clin Pharmacol Toxicol. 2013;113(4):273–9.CrossRefPubMed Kjaergaard AG, Dige A, Krog J, Tønnesen E, Wogensen L. Soluble adhesion molecules correlate with surface expression in an in vitro model of endothelial activation. Basic Clin Pharmacol Toxicol. 2013;113(4):273–9.CrossRefPubMed
17.
Zurück zum Zitat Dymicka-Piekarska V, Kemona H. Does colorectal cancer clinical advancement affect adhesion molecules (sP-selectin, sE-selectin and ICAM-1) concentration? Thromb Res. 2009;124(1):80–3.CrossRefPubMed Dymicka-Piekarska V, Kemona H. Does colorectal cancer clinical advancement affect adhesion molecules (sP-selectin, sE-selectin and ICAM-1) concentration? Thromb Res. 2009;124(1):80–3.CrossRefPubMed
18.
Zurück zum Zitat Basoğlu S, Atamanalp SS, Yildirgan MI, Aydinli B, Öztürk G, Akcay F, et al. Correlation between the serum levels of soluble intercellular adhesion molecule-1 and total sialic acid levels in patients with breast cancer. Eur Surg Res. 2007;39:136–40.CrossRefPubMed Basoğlu S, Atamanalp SS, Yildirgan MI, Aydinli B, Öztürk G, Akcay F, et al. Correlation between the serum levels of soluble intercellular adhesion molecule-1 and total sialic acid levels in patients with breast cancer. Eur Surg Res. 2007;39:136–40.CrossRefPubMed
19.
Zurück zum Zitat Hayes SH, Seigel GM. Immunoreactivity of ICAM-1 in human tumors, metastases and normal tissues. Int J Clin Exp Pathol. 2009;2:553–60.PubMedPubMedCentral Hayes SH, Seigel GM. Immunoreactivity of ICAM-1 in human tumors, metastases and normal tissues. Int J Clin Exp Pathol. 2009;2:553–60.PubMedPubMedCentral
20.
Zurück zum Zitat Kammerer S, Roth RB, Reneland R, Marnellos G, Hoyal CR, Markward NJ, et al. Large-scale association study identifies ICAM gene region as breast and prostate cancer susceptibility locus. Cancer Res. 2004;64(24):8906–10.CrossRefPubMed Kammerer S, Roth RB, Reneland R, Marnellos G, Hoyal CR, Markward NJ, et al. Large-scale association study identifies ICAM gene region as breast and prostate cancer susceptibility locus. Cancer Res. 2004;64(24):8906–10.CrossRefPubMed
21.
Zurück zum Zitat Ke JJ, Shao QS, Ling ZQ. Expression of E-selectin, integrin beta1 and immunoglobulin superfamily member in human gastric carcinoma cells and its clinicopathologic significance. World J Gastroenterol. 2006;12(22):3609–11.CrossRefPubMedPubMedCentral Ke JJ, Shao QS, Ling ZQ. Expression of E-selectin, integrin beta1 and immunoglobulin superfamily member in human gastric carcinoma cells and its clinicopathologic significance. World J Gastroenterol. 2006;12(22):3609–11.CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Tsoutsou PG, Gourgoulianis KI, Petinaki E, Mpaka M, Efremidou S, Maniatis A, et al. ICAM-1, ICAM-2 and ICAM-3 in the sera of patients with idiopathic pulmonary fibrosis. Inflammation. 2004;28(6):359–64.CrossRefPubMed Tsoutsou PG, Gourgoulianis KI, Petinaki E, Mpaka M, Efremidou S, Maniatis A, et al. ICAM-1, ICAM-2 and ICAM-3 in the sera of patients with idiopathic pulmonary fibrosis. Inflammation. 2004;28(6):359–64.CrossRefPubMed
23.
Zurück zum Zitat Adams DH, Mainolfi E, Burra P, Neuberger JM, Ayres R, et al. Detection of circulating intercellular adhesion molecule-1 in chronic liver diseases. Hepatology. 1992;16(3):810–4.CrossRefPubMed Adams DH, Mainolfi E, Burra P, Neuberger JM, Ayres R, et al. Detection of circulating intercellular adhesion molecule-1 in chronic liver diseases. Hepatology. 1992;16(3):810–4.CrossRefPubMed
24.
Zurück zum Zitat Zhang HY, Zhang Q, Zhang X, Yu C, Huo X, Cheng E, et al. Cancer-related inflammation and Barrett’s carcinogenesis: interleukin-6 and STAT3 mediate apoptotic resistance in transformed Barrett’s cells. Am J Physiol Gastrointest Liver Physiol. 2011;300(3):G454–60.CrossRefPubMed Zhang HY, Zhang Q, Zhang X, Yu C, Huo X, Cheng E, et al. Cancer-related inflammation and Barrett’s carcinogenesis: interleukin-6 and STAT3 mediate apoptotic resistance in transformed Barrett’s cells. Am J Physiol Gastrointest Liver Physiol. 2011;300(3):G454–60.CrossRefPubMed
25.
Zurück zum Zitat Rockett JC, Darnton SJ, Crocker J, Matthews HR, Morris AGJ. Expression of HLA-ABC, HLA-DR and intercellular adhesion molecule-1 in oesophageal carcinoma. J Clin Pathol. 1995;48(6):539–44.CrossRefPubMedPubMedCentral Rockett JC, Darnton SJ, Crocker J, Matthews HR, Morris AGJ. Expression of HLA-ABC, HLA-DR and intercellular adhesion molecule-1 in oesophageal carcinoma. J Clin Pathol. 1995;48(6):539–44.CrossRefPubMedPubMedCentral
26.
Zurück zum Zitat Hosch SB, Meyer AJ, Schneider C, Stoecklein N, Prenzel KL, Pantel K, et al. Expression and prognostic significance of HLA class I, ICAM-1, and tumor-infiltrating lymphocytes in esophageal cancer. J Gastrointest Surg. 1997;1(4):316–23.CrossRefPubMed Hosch SB, Meyer AJ, Schneider C, Stoecklein N, Prenzel KL, Pantel K, et al. Expression and prognostic significance of HLA class I, ICAM-1, and tumor-infiltrating lymphocytes in esophageal cancer. J Gastrointest Surg. 1997;1(4):316–23.CrossRefPubMed
27.
Zurück zum Zitat Moons LM, Kusters JG, Bultman E, Kuipers EJ, van Dekken H, Tra WM, et al. Barrett’s oesophagus is characterized by a predominantly humoral inflammatory response. J Pathol. 2005;207(3):269–76.CrossRefPubMed Moons LM, Kusters JG, Bultman E, Kuipers EJ, van Dekken H, Tra WM, et al. Barrett’s oesophagus is characterized by a predominantly humoral inflammatory response. J Pathol. 2005;207(3):269–76.CrossRefPubMed
28.
Zurück zum Zitat Abdel-Latif MM, O’Riordan J, Windle HJ, Carton E, Ravi N, Kelleher D, et al. NF-kappaB activation in esophageal adenocarcinoma: relationship to Barret’s metaplasia, survival, and response to neoadjuvant chemoradiotherapy. Ann Surg. 2004;239(4):491–500.CrossRefPubMedPubMedCentral Abdel-Latif MM, O’Riordan J, Windle HJ, Carton E, Ravi N, Kelleher D, et al. NF-kappaB activation in esophageal adenocarcinoma: relationship to Barret’s metaplasia, survival, and response to neoadjuvant chemoradiotherapy. Ann Surg. 2004;239(4):491–500.CrossRefPubMedPubMedCentral
29.
Zurück zum Zitat Colleypriest BJ, Stephen GW, David T. How does inflammation cause Barrett’s metaplasia? Curr Opin Pharmacol. 2009;9:721–6.CrossRefPubMed Colleypriest BJ, Stephen GW, David T. How does inflammation cause Barrett’s metaplasia? Curr Opin Pharmacol. 2009;9:721–6.CrossRefPubMed
30.
Zurück zum Zitat Bailey T, Biddlestone L, Shepherd N, Barr H, Warner P, Jankowski J. Altered cadherin and catenin complexes in the Barrett’s esophagus-dysplasia-adenocarcinoma sequence: correlation with disease progression and dedifferentiation. Am J Pathol. 1998;152(1):135–44.PubMedPubMedCentral Bailey T, Biddlestone L, Shepherd N, Barr H, Warner P, Jankowski J. Altered cadherin and catenin complexes in the Barrett’s esophagus-dysplasia-adenocarcinoma sequence: correlation with disease progression and dedifferentiation. Am J Pathol. 1998;152(1):135–44.PubMedPubMedCentral
31.
Zurück zum Zitat Miller SE, Veale RB. Environmental modulation of αv, α2 and β1 integrin subunit expression in human oesophageal squamous cell carcinomas. Cell Biol Int. 2001;25(1):61–9.CrossRefPubMed Miller SE, Veale RB. Environmental modulation of αv, α2 and β1 integrin subunit expression in human oesophageal squamous cell carcinomas. Cell Biol Int. 2001;25(1):61–9.CrossRefPubMed
32.
Zurück zum Zitat Takayama N, Arima S, Haraoka S, Kotho T, Futami K, Iwashita A. Relationship between the expression of adhesion molecules in primary esophageal squamous cell carcinoma and metastatic lymph nodes. Anticancer Res. 2003;23(6a):4435–42.PubMed Takayama N, Arima S, Haraoka S, Kotho T, Futami K, Iwashita A. Relationship between the expression of adhesion molecules in primary esophageal squamous cell carcinoma and metastatic lymph nodes. Anticancer Res. 2003;23(6a):4435–42.PubMed
33.
Zurück zum Zitat Tanaka Y, Mimori K, Shiraishi T, Ohkura Y, Takubo K, Mafune K, et al. α6 integrin expression in esophageal carcinoma. Int J Oncol. 2000;16(4):725–9.PubMed Tanaka Y, Mimori K, Shiraishi T, Ohkura Y, Takubo K, Mafune K, et al. α6 integrin expression in esophageal carcinoma. Int J Oncol. 2000;16(4):725–9.PubMed
34.
Zurück zum Zitat Rosette C, Roth RB, Oeth P, Braun A, Kammerer S, Ekblom J, et al. Role of ICAM1 in invasion of human breast cancer cells. Carcinogenesis. 2005;26(5):943–50.CrossRefPubMed Rosette C, Roth RB, Oeth P, Braun A, Kammerer S, Ekblom J, et al. Role of ICAM1 in invasion of human breast cancer cells. Carcinogenesis. 2005;26(5):943–50.CrossRefPubMed
35.
Zurück zum Zitat Liu Z, Guo B, Lopez RD. Expression of intercellular adhesion molecule (ICAM)-1 or ICAM-2 is critical in determining sensitivity of pancreatic cancer cells to cytolysis by human gammadelta-T cells: implications in the design of gammadelta-T-cell-based immunotherapies for pancreatic cancer. J Gastroenterol Hepatol. 2009;24(5):900–11.CrossRefPubMed Liu Z, Guo B, Lopez RD. Expression of intercellular adhesion molecule (ICAM)-1 or ICAM-2 is critical in determining sensitivity of pancreatic cancer cells to cytolysis by human gammadelta-T cells: implications in the design of gammadelta-T-cell-based immunotherapies for pancreatic cancer. J Gastroenterol Hepatol. 2009;24(5):900–11.CrossRefPubMed
36.
Zurück zum Zitat Yoon JK, Phelps DA, Bush RA, Remack JS, Billups CA, Khoury JD. ICAM-2 expression mediates a membrane-actin link, confers a nonmetastatic phenotype and reflects favorable tumor stage or histology in neuroblastoma. PLoS ONE. 2008;3(11):e3629.CrossRefPubMedPubMedCentral Yoon JK, Phelps DA, Bush RA, Remack JS, Billups CA, Khoury JD. ICAM-2 expression mediates a membrane-actin link, confers a nonmetastatic phenotype and reflects favorable tumor stage or histology in neuroblastoma. PLoS ONE. 2008;3(11):e3629.CrossRefPubMedPubMedCentral
37.
Zurück zum Zitat Park JK, Park SH, So K, Bae IH, Yoo YD, Um HD. ICAM-3 enhances the migratory and invasive potential of human non-small cell lung cancer cells by inducing MMP-2 and MMP-9 via Akt and CREB. Int J Oncol. 2010;36(1):181–92.PubMed Park JK, Park SH, So K, Bae IH, Yoo YD, Um HD. ICAM-3 enhances the migratory and invasive potential of human non-small cell lung cancer cells by inducing MMP-2 and MMP-9 via Akt and CREB. Int J Oncol. 2010;36(1):181–92.PubMed
38.
Zurück zum Zitat Vainer B, Nielsen OH. Changed colonic profile of P-selectin, platelet-endothelial cell adhesion molecule-1 (PECAM-1), intercellular adhesion molecule-1 (ICAM-1), ICAM-2, and ICAM-3 in inflammatory bowel disease. Clin Exp Immunol. 2000;121:242–7.CrossRefPubMedPubMedCentral Vainer B, Nielsen OH. Changed colonic profile of P-selectin, platelet-endothelial cell adhesion molecule-1 (PECAM-1), intercellular adhesion molecule-1 (ICAM-1), ICAM-2, and ICAM-3 in inflammatory bowel disease. Clin Exp Immunol. 2000;121:242–7.CrossRefPubMedPubMedCentral
39.
Zurück zum Zitat Tanaka H, Yashiro M, Sunami T, Sakate Y, Kosaka K, Hirakawa K. ICAM-2 gene therapy for peritoneal dissemination of scirrhous gastric carcinoma. Clin Cancer Res. 2004;10(14):4885–92.CrossRefPubMed Tanaka H, Yashiro M, Sunami T, Sakate Y, Kosaka K, Hirakawa K. ICAM-2 gene therapy for peritoneal dissemination of scirrhous gastric carcinoma. Clin Cancer Res. 2004;10(14):4885–92.CrossRefPubMed
40.
Zurück zum Zitat Maruo Y, Gochi A, Kaihara A, Shimamura H, Yamada T, Tanaka N, et al. ICAM-1 expression and the soluble ICAM-1 level for evaluating the metastatic potential of gastric cancer. Int J Cancer. 2002;100(4):486–90.CrossRefPubMed Maruo Y, Gochi A, Kaihara A, Shimamura H, Yamada T, Tanaka N, et al. ICAM-1 expression and the soluble ICAM-1 level for evaluating the metastatic potential of gastric cancer. Int J Cancer. 2002;100(4):486–90.CrossRefPubMed
41.
Zurück zum Zitat Bassi V, De Riu S, Feliciello A, Altomonte M, Allevato G, Rossi G, et al. Intercellular adhesion molecule-1 is upregulated via the protein kinase C pathway in human thyroid carcinoma cell lines. Thyroid. 1998;8(1):23–8.CrossRefPubMed Bassi V, De Riu S, Feliciello A, Altomonte M, Allevato G, Rossi G, et al. Intercellular adhesion molecule-1 is upregulated via the protein kinase C pathway in human thyroid carcinoma cell lines. Thyroid. 1998;8(1):23–8.CrossRefPubMed
42.
Zurück zum Zitat Arnold JM, Cummings M, Purdie D, Chenevix-Trench G. Reduced expression of intercellular adhesion molecule-1 in ovarian adenocarcinomas. Br J Cancer. 2001;85(9):1351–8.CrossRefPubMedPubMedCentral Arnold JM, Cummings M, Purdie D, Chenevix-Trench G. Reduced expression of intercellular adhesion molecule-1 in ovarian adenocarcinomas. Br J Cancer. 2001;85(9):1351–8.CrossRefPubMedPubMedCentral
43.
Zurück zum Zitat Ogawa Y, Hirakawa K, Nakata B, Fujihara T, Sawada T, Kato Y, et al. Expression of intercellular adhesion molecule-1 in invasive breast cancer reflects low growth potential, negative lymph node involvement, and good prognosis. Clin Cancer Res. 1998;4(1):31–6.PubMed Ogawa Y, Hirakawa K, Nakata B, Fujihara T, Sawada T, Kato Y, et al. Expression of intercellular adhesion molecule-1 in invasive breast cancer reflects low growth potential, negative lymph node involvement, and good prognosis. Clin Cancer Res. 1998;4(1):31–6.PubMed
Metadaten
Titel
Investigation of intercellular adhesion molecules (ICAMs) gene expressions in patients with Barrett's esophagus
verfasst von
Belgin Alasehirli
Elif Oğuz
Ebru Oksuzler
Irfan Koruk
Serdar Oztuzcu
Esma Ozkara
Metin Karakok
Ayse Binnur Erbagcı
Abdullah Tuncay Demiryurek
Publikationsdatum
01.05.2014
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 5/2014
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-014-1644-3

Weitere Artikel der Ausgabe 5/2014

Tumor Biology 5/2014 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.